Bausch Health Shares Surge 21% on Third-Quarter Beat, Higher Guidance
Bausch Health shares rose 21% after third-quarter profit topped expectations, supported by sales growth for its flagship gastrointestinal drug. The company upgraded its full-year guidance.
By Adriano MarcheseBausch Health surged after profit topped expectations in the third quarter, fueled by sales growth for its flagship gastrointestinal drug, and the pharmaceutical maker upgraded its guidance.Shares trading in Toronto rose 21% to 11.72 Canadian dollars ($8.37).The Laval, Quebec-bas…